Organon Files Preliminary Proxy for $14.00/Share Acquisition by Sun Pharma, Details Executive Compensation
OGN has more than doubled off its 52-week low of $5.69.
Summary
Organon filed a preliminary proxy statement for its acquisition by Sun Pharmaceutical at $14.00 per share, outlining the terms for shareholder approval and detailing executive compensation related to the merger.
Key Events · M&A and Partnerships · OGN
-
Merger Agreement Proposal
Shareholders will vote on the adoption of the Agreement and Plan of Merger, under which Organon will be acquired by Sun Pharmaceutical Holdings USA, Inc. for $14.00 per share in cash.
-
Executive Compensation Details
The filing discloses 'golden parachute' compensation for named executive officers, totaling approximately $69.6 million, contingent on the merger and qualifying termination events.
-
Board Recommendation
Organon's Board of Directors unanimously recommends that shareholders vote 'FOR' both the Merger Agreement Proposal and the non-binding advisory Compensation Proposal.
-
Equity Award Treatment
Outstanding stock options, restricted stock units (RSUs), and performance stock units (PSUs) will be cashed out or converted into cash-based awards by Sun Pharma USA, with certain 2026+ awards vesting upon a qualifying termination post-closing.
Analysis · OGN · Life Sciences
Organon has filed a preliminary proxy statement (PREM14A) seeking shareholder approval for its acquisition by Sun Pharmaceutical Holdings USA, Inc. for $14.00 per share in cash. This filing is a critical procedural step following the definitive merger agreement announced on April 27, 2026. The board unanimously recommends shareholders vote 'FOR' the merger and the related executive compensation. The offer price represents a premium over recent trading prices, and the stock is currently trading slightly below the offer price, indicating some market uncertainty regarding the deal's completion. The filing also details significant 'golden parachute' compensation for named executive officers, totaling approximately $69.6 million, which is a material amount relative to the company's market capitalization.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OGN was trading at $13.34 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $5.69 to $13.48. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.